CCL2/MCP1 Antibody

Immunohistochemistry-Paraffin: CCL2/MCP1 Antibody [20530002] - CCL2 is expressed by melanoma cells in tumor tissues from patients. CCL2 immunostaining of three representative tumor lesions showing low (upper), moderate (middle), or high (lower) staining intensity; these lesions were all stained positive for BRAFV600E. At the bottom, ISH showing the CCL2-specific signal in the tumor cells (black arrows); UBC staining was used as a control. Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/fulltext/6599) licensed under a CC-BY license.

Immunohistochemistry: CCL2/MCP1 Antibody [20530002] - Strong cytoplasmic positivity with additional staining of luminal membranes was seen in mucus-producing cells of the gastro-intestinal tract. Cells of the CNS and lymphoid tissues were in general negative, except for mast cells, which were strongly positive. In malignant tissues, mucin secreting colo-rectal carcinomas and mucinous cystadenocarcinomas of ovary exhibited strong cytoplasmic staining with additional positivity of luminal membranes. Few other adenocarcinomas were strongly stained in cytoplasm. Malignant gliomas, lymphomas and renal cancers were mainly negative. Image and statement courtesy of the Human Protein Atlas (HPA).

ELISA: CCL2/MCP1 Antibody [20530002]

Product Discontinued

CCL2/MCP1 Antibody Summary

• Immunogen: This antibody is specific for the entire range of the target protein.
• Specificity: This product is specific for Human CCL2.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: CCL2
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Flow Cytometry
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:10-1:500
• Application Notes: This antibody is useful in ELISA and Immunohistochemistry-Paraffin. Use in FLOW reported in scientific literature (PMID: 26684239).

Reactivity Notes

Human.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: 20mM Potassium Phosphate (pH 7.0) and 0.15M NaCl
• Preservative: No Preservative
• Purity: Immunogen affinity purified

Notes

Manufactured by SDIX's proprietary Genomic Antibody Technology™. GAT FAQs.

Alternate Names for CCL2/MCP1 Antibody

• C-C motif chemokine 2
• chemokine (C-C motif) ligand 2
• GDCF-2
• HC11Monocyte secretory protein JE
• MCAFMonocyte chemotactic and activating factor
• MCP1 Monocyte chemotactic protein 1
• MCP-1 Small-inducible cytokine A2
• MGC9434
• Monocyte chemoattractant protein 1
• monocyte chemoattractant protein-1
• SCYA2HSMCR30
• small inducible cytokine A2 (monocyte chemotactic protein 1, homologous tomouse Sig-je)
• small inducible cytokine subfamily A (Cys-Cys), member 2
• SMC-CF

Background

Monocyte chemoattractant protein-1 (MCP-1) is a member of the chemokine-beta family of cytokines. The protein is structurally related to the CXC subfamily of cytokines. Members of this subfamily are characterized by two cysteines separated by a single amino acid. This cytokine displays chemotactic activity for monocytes and basophils but not for neutrophils or eosinophils. It has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and atherosclerosis. It binds to chemokine receptors CCR2 and CCR4. It may play a inprotant role in the initiation and/or progression of pulmonary hypertension (PH). Blockade of a systemic MCP-1 signal pathway in vivo may prevent PH.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CCL2/MCP1 Antibody (20530002)(3)

Publications using 20530002

• Garrison C, Lastwika K, Zhang Y et al. Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections With Obesity J Proteome Res. 2017-01-06 [PMID: 27769113] (MiAr)
  
  Details:
  Analysis is performed on plasma proteomic data to identify how obesity can alter pathways and to highlight the risk factor for disease in subjects with a high body mass index.
• Vergani E, Di Guardo L, Dugo M et al. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. Oncotarget 2016-01-26 [PMID: 26684239] (FLOW)
• Rho JH, Lampe PD. High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays J Proteome Res. 2013-05-03 [PMID: 23541305] (MiAr)
  
  Details:
  A novel method using antibody microarrays is used to detect autoantibody-antigen complexes that can potentially be useful for detection and characterization of diseases.

Bioinformatics

• Gene Symbol: CCL2
• Uniprot:
  • NM_002982(Human)